{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:33:18Z","timestamp":1738042398831,"version":"3.33.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2\u20133 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma. However, prospective randomized trials including allogeneic stem cell transplantation as second-line therapy do not exist to date and therefore urgently needed to demonstrate the value of this therapy in the overall setting of patients with multiple myeloma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This clinical trial is a national, multicenter, randomized, open labeled phase III study conducted in 30 hospitals spread all over Germany. After study inclusion, all patients will receive 3 cycles of salvage therapy with one of the currently approved triplet regimens for first relapse. After 3 cycles of salvage therapy, remission status will be assessed. If the patient achieves at least stable disease, partial or complete remission and an HLA compatible stem cell donor could be identified, he\/she will be randomized (1:1) to the control or interventional study arm. Approximately 400 patients will be enrolled to enable a randomization of 280 patients. The primary endpoint is overall survival at five years after randomization. The main secondary objectives and endpoints are progression-free survival rate, time-to first occurrence of an infection with CTCAE grade 3\u20135, non-relapse mortality rate and incidence of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The present clinical study is designed to evaluate the superiority of allogeneic stem cell transplantation compared to conventional therapy (triplet chemotherapy) for the difference in overall survival at 5 years, toxicity and quality of life in patients with multiple myeloma who have relapsed or progressed after first-line autologous stem cell therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov (NCT05675319) registered on January 9, 2023.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13503-7","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T01:29:38Z","timestamp":1737941378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)"],"prefix":"10.1186","volume":"25","author":[{"given":"Annemarie","family":"Gl\u00f6ckner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"17","key":"13503_CR1","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519\u201329.","journal-title":"Blood"},{"key":"13503_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","volume":"100","author":"CC Kariyawasan","year":"2007","unstructured":"Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100:635\u201340.","journal-title":"QJM"},{"key":"13503_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10428190902741471","volume":"50","author":"CR Friese","year":"2009","unstructured":"Friese CR, Abel GA, Magazu LS, Neville BA, Richardson LC, Earle CC. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma. 2009;50:392\u2013400.","journal-title":"Leuk Lymphoma"},{"key":"13503_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings Mayo Clinic. 2003;78:21\u201333.","journal-title":"Mayo Clinic Proceedings Mayo Clinic"},{"issue":"2","key":"13503_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00277-020-04316-8","volume":"100","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Kr\u00f6ger N. The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review. Ann Hematol. 2021;100(2):405\u201319.","journal-title":"Ann Hematol"},{"issue":"4","key":"13503_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/10428194.2016.1228926","volume":"58","author":"L Garderet","year":"2017","unstructured":"Garderet L, et al. Treatment options for relapse after autograft in multiple myeloma \u2013 report from an EBMT educational meeting. Leuk Lymphoma. 2017;58(4):797\u2013808.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"13503_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","volume":"130","author":"JL Harousseau","year":"2017","unstructured":"Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130(8):963\u201373.","journal-title":"Blood"},{"issue":"9023","key":"13503_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","volume":"348","author":"J Aschan","year":"1996","unstructured":"Aschan J, L\u00f6nnqvist B, Ringd\u00e9n O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348(9023):346.","journal-title":"Lancet"},{"issue":"3","key":"13503_CR9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196\u20138.","journal-title":"Blood"},{"issue":"18","key":"13503_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","volume":"325","author":"G Gahrton","year":"1991","unstructured":"Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group of Bone Marrow Transplantation. N Engl J Med. 1991;325(18):1267\u201373.","journal-title":"N Engl J Med."},{"issue":"14","key":"13503_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"13503_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbmt.2017.10.014","volume":"24","author":"F Patriarca","year":"2018","unstructured":"Patriarca F, et al. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. Biol Blood Marrow Transplant. 2018;24(2):406\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"13503_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2307\/2530643","volume":"41","author":"S Greenland","year":"1985","unstructured":"Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55\u201368.","journal-title":"Biometrics"},{"issue":"25","key":"13503_CR14","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","volume":"121","author":"G Gahrton","year":"2013","unstructured":"Gahrton G, et al. Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055\u201363.","journal-title":"Blood"},{"issue":"5","key":"13503_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bmt.2009.14","volume":"44","author":"Y Khaled","year":"2009","unstructured":"Khaled Y, et al. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus myeloma effect. Bone Marrow Transplant. 2009;44(5):325\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"13503_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2009.07984.x","volume":"148","author":"N Kr\u00f6ger","year":"2010","unstructured":"Kr\u00f6ger N, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010;148(2):323\u201331.","journal-title":"Br J Haematol"},{"issue":"10","key":"13503_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/leu.2016.101","volume":"30","author":"M Sobh","year":"2016","unstructured":"Sobh M, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30(10):2047\u201354.","journal-title":"Leukemia"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13503-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:21:17Z","timestamp":1737984077000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13503"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13503-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is planned and performed in accordance with the Declaration of Helsinki 2013, the EU Clinical Trial Directive 2001\/20\/ EC that will be replaced by the new EU Clinical Trial Regulation 536\/ 2014 after transition in August 2024, the German Drug Law (Arzneimittelgesetz) in the current version as well as in accordance with the Good Clinical Practice (GCP) principles.The study protocol, the patient information sheet and the informed consent form were submitted to all involved ethics committees and approved before study start. In parallel, necessary documents were submitted to the competent authority (Paul-Ehrlich-Institute) for approval. The approval of both parties were mandatory for study conduct and recruiting of patients. The current study protocol version 5.0 of February 2024 was approved by the independent leading ethics committee (Ethik-Kommission der \u00c4rztekammer Hamburg; 2021\u2013100714-AMG-ff) and competent authority on the 21st of March 2024 and on the 26th of March 2024, respectively.Written informed consent from each patient is mandatory before any study treatments will be performed. The investigator explain the nature, significance and implications of the study. All methods, rules of conduct and any restrictions which may apply will be explained. Possible effects and side effects will be discussed. Patients will be informed that they are free to withdraw from the study at any time, without giving any reason.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}